Expert Review of Anticancer Therapy最新文献_第3页

Knockdown of TFB2M induces ferroptosis in lung adenocarcinoma via mitophagy-mediated GPX4 degradation. TFB2M的下调通过有丝自噬介导的GPX4降解诱导肺腺癌铁下垂。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-03 DOI: 10.1080/14737140.2025.2554642

Tulei Tian, Tianyu She, Meiling Xie, Xiangkun Qu, Hongbo Zhang, Gengyun Sun

{"title":"Knockdown of TFB2M induces ferroptosis in lung adenocarcinoma via mitophagy-mediated GPX4 degradation.","authors":"Tulei Tian, Tianyu She, Meiling Xie, Xiangkun Qu, Hongbo Zhang, Gengyun Sun","doi":"10.1080/14737140.2025.2554642","DOIUrl":"https://doi.org/10.1080/14737140.2025.2554642","url":null,"abstract":"Background: Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, with a low survival rate. TFB2M, a mitochondrial transcription factor, maintains normal mitochondrial function. Its role in LUAD is unclear.Methods: We analyzed TFB2M expression in LUAD and normal tissues based on TCGA database. GSEA analyzed pathway enrichment. TFB2M-knockdown LUAD and control groups were constructed. Western blot detected levels of mitophagy- and ferroptosis-related proteins with/without mitophagy inhibitor (Mdivi-1, 10 μM). Malondialdehyde, glutathione, 4-hydroxynonenal, reactive oxygen species, and Fe2+ levels were measured to evaluate ferroptosis. CCK-8, EdU experiments, and flow cytometry evaluated cell survival. Immunofluorescence detected co-localization of glutathione peroxidase 4 and mitochondrial outer membrane transferase 20. Mitochondrial-specific fluorescent probes evaluated mitochondrial changes. A LUAD xenograft mouse model was constructed, with tumor volume and weight (with/without mitophagy inhibitors, 50 mg/kg) measured. IHC detected TFB2M and ki67 expression.Results: TFB2M was upregulated (p < 0.05), and enriched in ferroptosis and mitophagy-related pathways. Mitophagy inhibitors reversed the promotion of mitophagy and ferroptosis and the inhibition of cell proliferation conferred by TFB2M knockdown. In animal experiments, they weakened the inhibition of mitophagy and the alleviation of LUAD progression induced by TFB2M knockdown.Conclusion: TFB2M contributes to ferroptosis resistance in LUAD by suppressing mitophagy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unmasking disparities in bladder cancer outcomes in the disaggregated Asian American population. 揭示亚裔美国人群膀胱癌结局的差异。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-03 DOI: 10.1080/14737140.2025.2556884

Wenjin An, Dong Shen, Dan Li, Jie Shen

{"title":"Unmasking disparities in bladder cancer outcomes in the disaggregated Asian American population.","authors":"Wenjin An, Dong Shen, Dan Li, Jie Shen","doi":"10.1080/14737140.2025.2556884","DOIUrl":"10.1080/14737140.2025.2556884","url":null,"abstract":"Background: Research on urothelial carcinoma of the bladder (UCUB) in non-Hispanic Asian American (NHAA) populations typically amalgamate all subgroups, masking significant intra-ethnic difference. This study aimed to examine variations in UCUB characteristics and outcomes within NHAA populations.Research design and methods: Patients with UCUB were identified from the Surveillance, Epidemiology, and End Results database. The NHAA cohort disaggregated into Chinese, Filipino, South Asian, Japanese, Korean, Vietnamese, and other Asian subgroups. Kaplan-Meier and Cox proportional hazards models were used to estimate unadjusted and adjusted overall survival (OS) and cancer-specific survival (CSS).Results: NHAA patients (n = 2,686) exhibited the longest median OS (88 months) compared to other cohorts (p < 0.001). Among NHAA subgroups, five-year OS rates ranged from 50% in Filipino patients to 64% in other Asian groups. In adjusted analyses, Chinese (HR 0.84, 95% CI 0.74-0.94), Korean (HR 0.74, 95% CI 0.61-0.91), and other Asian (HR 0.68, 95% CI 0.56-0.82) patients exhibited significantly reduced mortality risk relative to Non-Hispanic White patients.Conclusions: Filipino Americans faced comparatively poorer survival, while Chinese and Korean Americans showed more favorable prognoses. These findings highlight the need for targeted, culturally tailored interventions and refined risk stratification to enhance equity in the management of UCUB.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma. Nivolumab和ipilimumab治疗可切除的III期黑色素瘤的评估。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-06-21 DOI: 10.1080/14737140.2025.2522944

Alistair McCombe, Alexander C J van Akkooi

{"title":"An evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma.","authors":"Alistair McCombe, Alexander C J van Akkooi","doi":"10.1080/14737140.2025.2522944","DOIUrl":"10.1080/14737140.2025.2522944","url":null,"abstract":"Introduction: Twenty years ago, surgery was the centerpiece of treatment for cutaneous melanoma, including for resectable stage III and IV patients. The arrival of effective systemic therapies in the early 2010s has led to the abandonment of less effective traditional chemotherapeutic agents, a reduction in surgical excision margins, and a smaller set of indications for lymph node dissection. A more recent shift has been from adjuvant to neo-adjuvant immunotherapy for resectable macroscopic stage III melanoma. The speed at which the field is progressing, and the frequency of important publications on the topic, mean that regular review articles are useful to the scientific and wider community to keep abreast of this rapidly changing environment. PubMed and Cochrane databases were used to perform the literature search.Areas covered: We have contextualized the emergence of ipilimumab and nivolumab in the adjuvant and neo-adjuvant treatment of resectable stage III melanoma with discussion of pivotal studies, and how they influence the current guidelines.Expert opinion: The future is looking brighter for patients with Stage III melanoma. The pendulum has swung away from radical surgery, and toward less invasive procedures and bespoke systemic treatment options based on tumor characteristics, patient factors, and response to neo-adjuvant therapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"999-1005"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The argument for screening programs in previvors with Li-Fraumeni syndrome. Li-Fraumeni综合征患者筛查方案的争论。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-07-03 DOI: 10.1080/14737140.2025.2522943

Meis Omran, David Malkin

{"title":"The argument for screening programs in previvors with Li-Fraumeni syndrome.","authors":"Meis Omran, David Malkin","doi":"10.1080/14737140.2025.2522943","DOIUrl":"10.1080/14737140.2025.2522943","url":null,"abstract":"Introduction: Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by pathogenic/likely pathogenic germline TP53 variants. Core cancers include sarcomas, brain tumors, adrenocortical carcinoma and breast cancer. Surveillance with whole-body MRI (WBMRI) and other modalities is used for early cancer detection, regardless of the individual's personal cancer history. With the increasing use of diagnostic multigene panels in oncology, more diverse phenotypic presentations have emerged, and subsequent cascade testing identifies more asymptomatic cancer-free individuals - 'previvors.'Areas covered: This review analyzes aspects of early cancer detection screening programs in asymptomatic germline TP53 variant carriers including current guidelines, specific founder variant populations, health economics and emerging strategies including liquid biopsies and wearable devices. A literature search with PubMed included publications in English until April 2025.Expert opinion: Current guidelines recommend WBMRI in all LFS individuals, regardless of their prior cancer history, due to its demonstrated survival advantage. Guidelines for use of other modalities such as endoscopy, ultrasound or laboratory tests are less well-established. Therefore, longitudinal prospective studies including all these modalities and their cancer detection rates are needed. In the future, a one-size-fits-all approach toward surveillance will be replaced by more precise patient-centered tailor-made screening programs incorporating noninvasive methods.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1065-1074"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol. Gustave Roussy免疫评分作为预测异柠檬酸脱氢酶野生型胶质母细胞瘤患者生存的一种新的生物标志物。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 DOI: 10.1080/14737140.2025.2555467

Asim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, Erkan Kayikcioglu, Kamuran Yuceer, Gizem Zorlu Gorgulugil, Ridvan Yavuz, Mehmet Acun, Ece Ulukal Karanci, Banu Ozturk, Mustafa Yildiz

{"title":"The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol.","authors":"Asim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, Erkan Kayikcioglu, Kamuran Yuceer, Gizem Zorlu Gorgulugil, Ridvan Yavuz, Mehmet Acun, Ece Ulukal Karanci, Banu Ozturk, Mustafa Yildiz","doi":"10.1080/14737140.2025.2555467","DOIUrl":"https://doi.org/10.1080/14737140.2025.2555467","url":null,"abstract":"Background: Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is a biologically aggressive adult-type diffuse glioma with poor prognosis. Gustave Roussy Immune Score (GRIm-Score), reflecting systemic inflammation and nutritional status, has shown prognostic relevance in several cancers. Its prognostic value in IDH-wt glioblastoma remains undefined.Methods: This retrospective single-center study included 186 patients with histologically confirmed IDH-wt glioblastoma. GRIm-Score was calculated using pretreatment NLR, albumin, and lactate dehydrogenase (LDH) levels. Patients were grouped into low- and high-risk categories. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Correlations with other inflammation-based indices, such as PILE, CAR, and PIV, were also examined.Results: A high GRIm-Score was significantly associated with reduced OS and PFS. Patients with higher scores more frequently exhibited poor prognostic features, including advanced age, worse ECOG performance, limited treatment response, and subtotal resection. Multivariate analysis identified GRIm-Score as an independent prognostic factor, particularly when analyzed alongside CAR and PIV. Strong correlations were observed between GRIm-Score and other immuno-nutritional markers.Conclusions: GRIm-Score is a simple and reliable prognostic indicator in IDH-wt glioblastoma. Its routine use may improve risk stratification and inform therapeutic decisions. Further prospective multicenter validation is warranted.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators. 紫杉醇联合贝伐单抗腹腔内滴注治疗常见胃肠道恶性腹膜积液的疗效分析及预后指标筛选

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-06-21 DOI: 10.1080/14737140.2025.2522251

Yucong Li, Xuguang Mi, Xiaonan Li, Xiao-Nan Li, Ying Yang, Ying Zhou, Xianzhuo Jiang, Yingying Yu, Zhiqiang Ni, JunZi Zhang, Xiuying Lin, Yanqiu Fang, Junjie Hou

{"title":"Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators.","authors":"Yucong Li, Xuguang Mi, Xiaonan Li, Xiao-Nan Li, Ying Yang, Ying Zhou, Xianzhuo Jiang, Yingying Yu, Zhiqiang Ni, JunZi Zhang, Xiuying Lin, Yanqiu Fang, Junjie Hou","doi":"10.1080/14737140.2025.2522251","DOIUrl":"10.1080/14737140.2025.2522251","url":null,"abstract":"Background: This study investigates the efficacy of paclitaxel combined with bevacizumab in the treatment of malignant gastrointestinal tumors with malignant ascites and screens for biomarkers that predict efficacy.Research design and methods: A prospective cohort study was conducted, enrolling 92 eligible patients who received either paclitaxel combined with bevacizumab or paclitaxel monotherapy. Efficacy was assessed, and biomarkers predictive of treatment efficacy were screened using indicators such as disease control rate, objective response rate, LA, LDH, and CD4+/CD8+ ratios.Results: The disease control rate (91.18%) and objective response rate (61.76%) in both the treatment group and the control group were significantly better than those in the control group. In the treatment group, non-PD group, and remission group, LA and LDH levels decreased significantly with increasing number of treatments, while the CD4+/CD8+ ratio increased significantly. There was no significant difference between the control group and the non-relief group after treatment. The trend of changes after PD treatment was opposite to that mentioned above. There was no statistically significant difference in adverse reactions between the two groups.Conclusion: This study demonstrated that the combination of paclitaxel and bevacizumab is more effective and that LA, LDH, and CD4+/CD8+ can predict treatment efficacy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1111-1119"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data. 阿比特龙治疗转移性激素敏感前列腺癌的疗效：基于低或高疾病量亚组和重建个体患者数据的分层荟萃分析

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-06-26 DOI: 10.1080/14737140.2025.2522981

Fuxun Zhang, Zhirong Luo, Qi Xue, Xuyan Guo, Qiang Fu, Yong Jiao, Wei Zhang, Yang Xiong, Pati-Alam Alisha, Uzoamaka Adaobi Okoli, Geng Zhang

{"title":"The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data.","authors":"Fuxun Zhang, Zhirong Luo, Qi Xue, Xuyan Guo, Qiang Fu, Yong Jiao, Wei Zhang, Yang Xiong, Pati-Alam Alisha, Uzoamaka Adaobi Okoli, Geng Zhang","doi":"10.1080/14737140.2025.2522981","DOIUrl":"10.1080/14737140.2025.2522981","url":null,"abstract":"Introduction: The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain. This meta-analysis aims to clarify benefit of abiraterone in low- and high-volume mHSPC.Research design and methods: Phase III randomized clinical trials of abiraterone were selected. Individual patient data (IPD) for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy. Survival analysis was performed using Cox hazards model.Results: Data for 3374 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59-0.73) and PFS (HR: 0.51, 95% CI 0.45-0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1-2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3-4 events increased (RR 1.33). The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All p < 0.05).Conclusions: Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation shouldvalidate these findings in real world setting.Registration: PROSPERO: (CRD420251028079).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1099-1109"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation. EGFR-TKI联合治疗egfr敏感突变的NSCLC。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-07-01 DOI: 10.1080/14737140.2025.2520962

Yuanqiang Wu, Yunfei Li, Lorraine Edna Onzere, Weini Quan, Xueqing Zhang, Jin'an Ma

{"title":"EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation.","authors":"Yuanqiang Wu, Yunfei Li, Lorraine Edna Onzere, Weini Quan, Xueqing Zhang, Jin'an Ma","doi":"10.1080/14737140.2025.2520962","DOIUrl":"10.1080/14737140.2025.2520962","url":null,"abstract":"Introduction: Lung cancer is the leading cause of cancer-related deaths. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have opened up a new therapeutic avenue for EGFR-sensitive mutated non-small cell lung cancer (NSCLC), but their resistance is unavoidable. Overcoming the resistance is desperately desired. Combined treatments are partially efficient to address EGFR-TKIs resistance.Areas covered: Combination therapies function through various mechanisms, prevent the enrichment of resistant clones, synergistically enhance efficacy, and delay the onset of resistance. This article reviews the current research of combination therapy based on EGFR-TKIs for EGFR-mutated NSCLC to identify the most effective and least harmful combined regimen. A search of the literature on PubMed, Web of Science, and Embase databases was performed without filters.Expert opinion: The optimal treatment for EGFR-mutated NSCLC is still an open issue. EGFR-TKIs combined with anti-angiogenic drugs can bring short-term efficacy, but not benefit long-term survival and instead increase adverse reactions (AEs). The short-term efficacy of EGFR-TKIs combined with chemotherapy is clear, but the long-term efficacy varies in different studies, with significant benefits in certain subgroups. EGFR-TKIs combined with immune checkpoint inhibitors (ICIs) show a trend toward efficacy benefit; however, their high AEs require further optimization of the combination regimen.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1045-1056"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis. PD-1/PD-L1抑制剂联合化疗与单独化疗治疗tkis耐药、egfr突变的晚期非小细胞肺癌：一项基于3期随机对照试验的meta分析

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-07-08 DOI: 10.1080/14737140.2025.2522980

Xi Chen, Jianhua Zhao, Wenxiong Zhang, Xueming Ying

{"title":"PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis.","authors":"Xi Chen, Jianhua Zhao, Wenxiong Zhang, Xueming Ying","doi":"10.1080/14737140.2025.2522980","DOIUrl":"10.1080/14737140.2025.2522980","url":null,"abstract":"Background: Immunotherapy combined with chemotherapy has emerged as a potential strategy to overcome tyrosine kinase inhibitors (TKIs)-resistant for advanced non-small-cell lung cancer (NSCLC); however, the efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy (PIC) compared to chemotherapy alone require further investigation.Research design and methods: Phase III randomized controlled trials (RCTs) were systematically searched from 6 databases. Pooled hazard ratios (HRs) for survival outcomes and risk ratios (RRs) for responses and adverse events (AEs) were calculated.Results: Three phase III RCTs were included in the final analysis. The PIC therapy significantly improved overall survival (OS) (HR: 0.86, 95% CI: 0.75-1.00, p = 0.04) and progression-free survival (PFS) (HR: 0.78, 95% CI: 0.68-0.90, p = 0.0005) compared to chemotherapy alone. While PIC therapy improved survival in the overall population, no significant benefit was observed for patients with brain metastases and non-sensitizing EGFR mutations. However, the incidence of immune-related AEs (irAEs) (RR: 2.02, 95% CI: 1.45-2.81, p < 0.0001) and grade 3-5 irAEs (RR: 2.02, 95% CI: 1.03-3.98, p = 0.04) were increased.Conclusions: PIC therapy may provide a survival benefit for patients with TKIs-resistant, EGFR-mutant advanced NSCLC. Moreover, this potential benefit should be weighed against the increased risk of irAEs.Registration: PROSPERO (CRD42024615907).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1087-1098"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma. selinexor作为p53野生型、晚期或复发性子宫内膜癌患者维持治疗的评价

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-06-29 DOI: 10.1080/14737140.2025.2522948

Robert L Coleman, Pratheek Kalyanapu, Christopher J Walker, Ignace Vergote

{"title":"An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma.","authors":"Robert L Coleman, Pratheek Kalyanapu, Christopher J Walker, Ignace Vergote","doi":"10.1080/14737140.2025.2522948","DOIUrl":"10.1080/14737140.2025.2522948","url":null,"abstract":"Introduction: Tumor protein 53 gene (TP53) is the most frequently mutated gene in human cancers. TP53 mutation status may have prognostic value across malignancy types, and its use as a predictive biomarker is limited. Selinexor is a novel oral exportin 1 (XPO1) inhibitor with preliminary efficacy data as a maintenance treatment in advanced/recurrent TP53 wild-type (wt) endometrial cancer (EC), suggesting TP53wt may be a predictive biomarker for this therapy. XPO1 mediates nuclear to cytoplasmic trafficking of transcriptionally active p53, where it is degraded and rendered functionally inactive. Selinexor prevents this export to restore nuclear p53 and increase the transcription of p53 activated target genes.Areas covered: This review examines the mechanism of action of selinexor related to p53, contextualizes the effectiveness of selinexor among EC subtypes within the context of the evolving diagnostic, predictive, and therapeutic landscape for treatment, and presents the relevant clinical studies for selinexor dose for its use in gynecological malignancies. Literature review was conducted on the PubMed database.Expert opinion: The promising efficacy signal suggests selinexor has potential as a maintenance therapy for TP53wt EC to address current treatment gaps. A phase 3 study is currently enrolling to further evaluate its role in patients with advanced/recurrent EC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1007-1019"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0